Institute seminar May 25th 10.30 Per O. Seglen

Sohlberg E, Malmberg KJ (2025)
The innate power of natural killer cells in cancer therapy
Nat Med (in press)
DOI 10.1038/s41591-025-03712-9, PubMed 40355615

Trachsel-Moncho L, Mathai BJ, Veroni C, Simonsen A (2025)
SNX10 at the crossroad of endocytosis and piecemeal mitophagy
Autophagy, 1-3 (in press)
DOI 10.1080/15548627.2025.2499641, PubMed 40327657

Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK (2025)
Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50
ESMO Open, 10 (5), 105073 (in press)
DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908

Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS (2025)
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Clin Cancer Res, 31 (10), 1943-1955
DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050

Sohlberg E, Malmberg KJ (2025)
The innate power of natural killer cells in cancer therapy
Nat Med (in press)
DOI 10.1038/s41591-025-03712-9, PubMed 40355615

Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Å, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, Stenzinger A (2025)
Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access
Future Oncol, 1-8 (in press)
DOI 10.1080/14796694.2025.2501523, PubMed 40340714